scholarly journals Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort

2013 ◽  
Vol 19 (7) ◽  
pp. 646-653 ◽  
Author(s):  
C. Manzardo ◽  
A. Esteve ◽  
N. Ortega ◽  
D. Podzamczer ◽  
J. Murillas ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Optimal Timing ◽  
Highly Active ◽  
Immunodeficiency Virus ◽  
Treatment Naïve ◽  
Human Immunodeficiency Virus 1

scholarly journals Malignancies, Particularly B-Cell Lymphomas, Are a Frequent Cause of Mortality in Human Immunodeficiency Virus-1 Patients Despite Highly Active Antiretroviral Therapy

2015 ◽  
Vol 2 (4) ◽  
Author(s):  
Daniel O. Griffin ◽  
Michael Metzger ◽  
Kaitlin Poeth ◽  
Kathy Deng ◽  
Arif Dharsee ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Antiretroviral Therapy ◽  
B Cell ◽  
Highly Active Antiretroviral Therapy ◽  
B Cell Lymphomas ◽  
Highly Active ◽  
Immunodeficiency Virus ◽  
Hiv 1 ◽  
Human Immunodeficiency Virus 1 ◽  
Hiv Negative

Abstract Human immunodeficiency virus (HIV)-1-infected individuals are affected by diseases at rates above those of their HIV-negative peers despite the increased life expectancy of the highly active antiretroviral therapy era. We followed a cohort of approximately 2000 HIV-1-infected patients for 5 years. The most frequent cause of death in this HIV-1-infected cohort was malignancy, with 39% of all classified deaths due to cancer. Among the cancer deaths, B-cell lymphomas were the most commonly seen malignancy, representing 34% of all cancer deaths. These lymphomas were very aggressive with a median survival of <2 months from time of diagnosis.

Sign in / Sign up

Export Citation Format

Share Document